TScan cuts 75% of staff

TScan Therapeutics said on September 2 that it is cutting about 75% of its workforce as part of a strategic reorganization that pauses parts of its pipeline and narrows its focus to in vivo-engineered TCR-T candidates for solid tumors. The company said the plan is expected to save $55 million through the end of 2027 and extend its cash runway into the fourth quarter of 2027. In an 8-K filing, TScan said it is also eliminating its internal manufacturing organization and significantly reducing its research footprint. ### What exactly is TScan shutting down or slowing? TScan said the reorganization includes pausing further enrollment in its Phase 3 ALLOHA-2 study of TSC-101. The company said it will prioritize preclinical development of its in vivo solid tumor program while seeking strategic partnerships to preserve potential value in other programs. (sec.gov) The September 2 filing said the workforce reduction was tied to that prioritization strategy. TScan did not frame the move as a temporary hiring adjustment; it described a broader reset of operations, manufacturing and research around a smaller set of programs. ### Why is the cash runway number getting so much attention? (sec.gov) The company said its available cash, cash equivalents and marketable securities as of June 30, 2026, should be sufficient to fund planned operations into the fourth quarter of 2027. That guidance came alongside the projected $55 million in cumulative savings through the end of 2027. (sec.gov) Biotech companies often pair layoffs with runway updates because investors focus on how long a company can operate before raising more money. In TScan’s case, the company linked the staff cuts directly to extending that timeline while concentrating capital on fewer programs. (sec.gov) ### Is TScan the only cell-therapy company making this kind of move? ArsenalBio said on September 1 that it was cutting 99 employees as it pivoted toward in vivo CAR-T therapies. BioSpace reported the reduction affected the majority of the company’s staff and followed a prior 50% downsizing last year. (ir.tscan.com) Fierce Biotech and other trade outlets reported that ArsenalBio is stopping development of its ex vivo clinical assets and keeping a core team to advance the in vivo strategy. The sequence is notable because both companies are narrowing around in vivo approaches while reducing headcount. (biospace.com) ### Where does the Montefiore nurse dispute fit into this? Montefiore Health System’s situation is different from the biotech restructurings, but it has drawn attention because the job cuts were tied to AI by the nurses’ union. Crain’s New York Business reported in July that Montefiore planned to lay off 12 utilization-review nurses and replace their work with an artificial-intelligence platform, according to the New York State Nurses Association. (fiercebiotech.com) Nurse.org reported the layoffs were set to take effect by July 12, 2026, and said the union linked the work shift to Datavant software. Gadget Review later reported that the nurses lost their jobs months after a strike that had produced contract language on AI protections. Montefiore’s case remains a labor dispute over how much of the work is being automated and whether the move complies with the contract. (crainsnewyork.com) ### So what ties these three developments together? The common thread is not that the companies or institutions are doing the same thing. TScan and ArsenalBio are biotech companies cutting staff to conserve cash and refocus research, while the Montefiore dispute centers on whether administrative clinical work can be shifted from licensed nurses to software. (nurse.org) The immediate next steps are specific. TScan said the restructuring began September 2 and is tied to its revised development plan; ArsenalBio has already disclosed its 99-person reduction; and Montefiore’s dispute continues through union challenges over the July layoffs and the use of Datavant’s platform. (sec.gov)